I also see the company as an attractive acquisition target and believe that the decision on what to do outside the U.S. will provide a strong indication of its medium-term plans – partnering ex-U.

Source: https://seekingalpha.com/article/4621533-tg-therapeutics-addressing-the-sc-ocrevus-concern?source=feed_all_articles

Perhaps I will comment for the U.S. and then turn it over to Jacob more broadly for the ex-U.

Source: https://seekingalpha.com/article/4650831-h-lundbeck-s-hlukf-q3-2023-earnings-call-transcript?source=feed_all_articles

The next table compares the valuation and growth metrics of VSS, an ex-U.

Source: https://seekingalpha.com/article/4659983-vss-well-ranked-in-the-global-small-cap-etf-category?source=feed_all_articles